Efficacy of Tumor-Infiltrating Lymphocytes Combined with IFN-α in Chinese Resected Stage III Malignant Melanoma

Table 2

Treatment group outcomes.

Treatment group	DFS			OS
	Arm 1	Arm 2		Arm 1	Arm 2
1-year DFS or OS rates	48.21% (95% CI 29.76–64.46%)	28.00% (95% CI 16.45–40.75%)	0.04	92.59% (95% CI 73.50–98.09%)	78.00% (95% CI 63.81–87.16%)	0.03
2-year DFS or OS rates	33.38% (95% CI 17.80–49.78%)	2.00% (95% CI 0.16–9.23%)	0.00	62.96% (95% CI 42.12–78.07%)	32.00% (95% CI 19.70–44.97%)	0.00
3-year DFS or OS rates	25.96% (95% CI 12.47–41.75%)	0% (95% CI 0-0%)	0.00	55.56% (95% CI 35.22–71.81%)	16.00% (95% CI 7.50–27.37%)	0.00
5-year DFS or OS rates	—	—	—	48.14% (95% CI 28.69–65.19%)	12.00% (95% CI 4.88–22.60%)	0.00